Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)

SHA:605177 Revenue

Zhejiang East Asia Pharmaceutical had revenue of 142.82M CNY in the quarter ending September 30, 2026, a decrease of -20.87%. This brings the company's total for the last twelve months to 952.80M, up 14.58% year-over-year. In the year 2025, Zhejiang East Asia Pharmaceutical had annual revenue of 940.19M, down -21.54%. That makes Zhejiang East Asia Pharmaceutical the 20,002nd largest company in the world by revenue and 3,671st in China.

• Revenue (ttm): 952.80M
• Revenue Growth: +14.58%
• P/S Ratio: 2.51
• Revenue / Employee: 629.33K
• Employees: 1,514
• Market Cap: 2.39B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• ß-lactam antibiotics 481.76M 53.2%
• Anticholinergics and Synthetic Antispasmodics 197.10M 21.7%
• Quinolones Antibiotics 108.30M 12.0%
• Antifungal drugs for skin 71.61M 7.9%
• Other Products 47.43M 5.2%

By Geography

Chart

• China 700.77M 77.3%
• Overseas 205.42M 22.7%

Fiscal year ended Dec 31, 2025 See the full SHA:605177 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	940.19M	-258.05M	-21.54%
Dec 31, 2024	1.20B	-158.21M	-11.66%
Dec 31, 2023	1.36B	176.89M	15.00%
Dec 31, 2022	1.18B	467.34M	65.62%
Dec 31, 2021	712.22M	-169.45M	-19.22%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error